| CMND |
Clearmind Medicine Inc. |
72%
|
Reciprocal relationship from CMND graph: Reciprocal relationship from SPRC graph: Reciprocal relationship from CMND graph: Reciprocal relationship from SPRC graph: NOTE 7:- INVESTMENT IN ASSOCIATES M… |
| CMND |
Clearmind Medicine Inc. |
72%
|
NOTE 7:- INVESTMENT IN ASSOCIATES MitoCareX Transaction On March 10, 2022, the Company entered into a Founders and Investment Agreement with Dr. Alon Silberman (the “MitoCareX Agreement”). Pursuant t… |
| ESLT |
Elbit Systems Ltd. |
72%
|
Reciprocal relationship from ESLT graph: Reciprocal relationship from SPRC graph: aceutical product candidates in the next few years. As of December 31, 2025, our cash and cash equivalents, including… |
| ESLT |
Elbit Systems Ltd. |
72%
|
aceutical product candidates in the next few years. As of December 31, 2025, our cash and cash equivalents, including restricted deposits, was $4.6 million. Our cash and cash equivalents position is … |
| FRSX |
Foresight Autonomous Holdings Ltd. |
72%
|
aceutical product candidates in the next few years. As of December 31, 2025, our cash and cash equivalents, including restricted deposits, was $4.6 million. Our cash and cash equivalents position is … |
| FRSX |
Foresight Autonomous Holdings Ltd. |
72%
|
Reciprocal relationship from FRSX graph: Reciprocal relationship from SPRC graph: aceutical product candidates in the next few years. As of December 31, 2025, our cash and cash equivalents, including… |
| NEXRW |
NEXRW |
72%
|
aceutical product candidates in the next few years. As of December 31, 2025, our cash and cash equivalents, including restricted deposits, was $4.6 million. Our cash and cash equivalents position is … |
| NEXRW |
NEXRW |
72%
|
Reciprocal relationship from NEXRW graph: Reciprocal relationship from SPRC graph: aceutical product candidates in the next few years. As of December 31, 2025, our cash and cash equivalents, includin… |
| NNDM |
Nano Dimension Ltd. |
72%
|
aceutical product candidates in the next few years. As of December 31, 2025, our cash and cash equivalents, including restricted deposits, was $4.6 million. Our cash and cash equivalents position is … |
| NNDM |
Nano Dimension Ltd. |
72%
|
Reciprocal relationship from NNDM graph: Reciprocal relationship from SPRC graph: aceutical product candidates in the next few years. As of December 31, 2025, our cash and cash equivalents, including… |
| NXTS |
NXTS |
72%
|
NOTE 7:- INVESTMENT IN ASSOCIATES MitoCareX Transaction On March 10, 2022, the Company entered into a Founders and Investment Agreement with Dr. Alon Silberman (the “MitoCareX Agreement”). Pursuant t… |
| NXTS |
NXTS |
72%
|
Reciprocal relationship from NXTS graph: Reciprocal relationship from SPRC graph: NOTE 7:- INVESTMENT IN ASSOCIATES MitoCareX Transaction On March 10, 2022, the Company entered into a Founders and In… |
| PRZO |
ParaZero Technologies Ltd. |
72%
|
Reciprocal relationship from PRZO graph: Reciprocal relationship from SPRC graph: Reciprocal relationship from PRZO graph: Reciprocal relationship from SPRC graph: aceutical product candidates in the… |
| PRZO |
ParaZero Technologies Ltd. |
72%
|
aceutical product candidates in the next few years. As of December 31, 2025, our cash and cash equivalents, including restricted deposits, was $4.6 million. Our cash and cash equivalents position is … |
| RVSN |
Rail Vision Ltd. |
72%
|
aceutical product candidates in the next few years. As of December 31, 2025, our cash and cash equivalents, including restricted deposits, was $4.6 million. Our cash and cash equivalents position is … |
| RVSN |
Rail Vision Ltd. |
72%
|
Reciprocal relationship from RVSN graph: Reciprocal relationship from SPRC graph: aceutical product candidates in the next few years. As of December 31, 2025, our cash and cash equivalents, including… |
| AUTOMAX-MOTORS-LTD |
AUTOMAX-MOTORS-LTD |
62%
|
e required by the FDA, the European Medicines Agency, or the EMA, or other regulatory agencies, domestic or foreign, to perform clinical, nonclinical or other types of studies in addition to those th… |
| BRANDS-HOLDINGS-INC |
BRANDS-HOLDINGS-INC |
62%
|
ental approvals, permits and licenses; ● failure by us to obtain regulatory approvals for the use of our products in various countries; 48 ● additional potentially relevant third-party patent rights;… |
| CAPITAL-POINT-LTD |
CAPITAL-POINT-LTD |
62%
|
l to meet all applicable Nasdaq Capital Market requirements, Nasdaq could delist our Ordinary Shares, which could adversely affect the market liquidity of our Ordinary Shares and the market price of … |
| CLINIQUANTUM-LTD |
CLINIQUANTUM-LTD |
62%
|
ire in the near term. Upon the expiration of a patent, the protections afforded by such patent cease and third parties may be free to manufacture, use, sell, or import products or technologies that w… |
| DEKEL-PHARMACEUTICALS-LTD |
DEKEL-PHARMACEUTICALS-LTD |
62%
|
NOTE 15:- EMPLOYEE BENEFIT LIABILITIES Employee benefits consist of short-term benefits and post-employment benefits. Post-employment benefits: According to the labor laws and the Israeli Severance P… |
| EVERO-HEALTH-LTD |
EVERO-HEALTH-LTD |
62%
|
l to meet all applicable Nasdaq Capital Market requirements, Nasdaq could delist our Ordinary Shares, which could adversely affect the market liquidity of our Ordinary Shares and the market price of … |
| KEEPZONE-AI-INC |
KEEPZONE-AI-INC |
62%
|
ental approvals, permits and licenses; ● failure by us to obtain regulatory approvals for the use of our products in various countries; 48 ● additional potentially relevant third-party patent rights;… |
| MIZA-III-VENTURES-INC |
MIZA-III-VENTURES-INC |
62%
|
. In addition, in consideration for the License, the Company will receive royalties from sales related to the Assets and income generated from it. On April 1, 2025, the Company entered into a securit… |
| NASDAQ-STOCK-MARKET-LLC |
NASDAQ-STOCK-MARKET-LLC |
62%
|
e listing of Miza’s securities on either the New York Stock Exchange or the Nasdaq Stock Market LLC (each, a “U.S. Exchange”), or another transaction resulting in the issuance of shares listed on a U… |
| NEUROTHERA-LABS-INC |
NEUROTHERA-LABS-INC |
62%
|
of the Closing Date in equity and/or debt financing, of an aggregate of US$ 10 million or more; and (iii) 16,000,000 Miza Common Shares will be issued upon Miza completing a clinical trial within for… |
| XYLO-TECHNOLOGIES-LTD |
XYLO-TECHNOLOGIES-LTD |
62%
|
ard-looking statements. Any forward-looking statements in this Annual Report are made as of the date hereof, and we undertake no obligation to publicly update or revise any forward-looking statements… |
| YISSUM-RESEARCH-DEVELOPMENT-COMPANY |
YISSUM-RESEARCH-DEVELOPMENT-COMPANY |
62%
|
NOTE 15:- EMPLOYEE BENEFIT LIABILITIES Employee benefits consist of short-term benefits and post-employment benefits. Post-employment benefits: According to the labor laws and the Israeli Severance P… |
